Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The market for chimeric antigen receptor T cell therapies

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: 2026 sales forecast of branded therapies and market share for each drug class for relapsed or refractory haematologic malignancies.

Author information



Corresponding author

Correspondence to Rachel M. Webster.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yip, A., Webster, R. The market for chimeric antigen receptor T cell therapies. Nat Rev Drug Discov 17, 161–162 (2018).

Download citation

Further reading


Quick links